APVO

Aptevo Therapeuticsdistress 7/10 · high distress / dilution risk

$4.45+1%today-92% from 52w high

aptevotherapeutics.com33 employeesFounded 2016Seattle, WABiotechnology

Lead: Acute Myeloid Leukemia (AML) · target CD123 · est. market ~$15B (approx, global)

Revenue

pre-revenue

Liquidity

$15M

Runway

0.5 yrs

Shares 1y

-62%

Price & events

-50.2% over 6M

CatalystRating changeDilutionFinancingdashed = today

+0.7%

-2.6%

-6.3%

-13.3%

-50.2%

-92.1%

-99.9%

-100.0%

All

Overview

Market Cap: $5.55M
Volume: 18.50K
52 Week Range: $3.94 – $58.32
Total Shares: 1.25M
Float Shares: 1.09M
Short %: 6.38%
% Held by Insiders: 7.97%
% Held by Institutions: 4.45%
RVOL: 0.26x
Beta: 1.67

Pipeline stages · 1 programs

APVO436, Venetoclax, Azacitidine

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

next 2027-10

Pipeline · 2 trials · 1 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
2027-10 Estimated 50% readout ~2027-10-31	Phase 1	APVO436, Venetoclax, Azacitidine	Acute Myeloid Leukemia (AML)	—	recruiting
2026-01	Phase 1	APVO436	AML	0	withdrawn

Catalyst news & presentations · 7

first quarter of 2027Guided 70%trial initiationsecondaryAPVO451 · Initiation of IND-enabling studiesSEC 8-K
this yearGuided 40%readoutPhase 1mipletamig · Completion of Phase 1b dose-optimization trial and selection of recommended Phase 2 doseSEC 8-K
2026-06-30partnershipAPVO451 · Secured $1.5M non-dilutive research grant from Andy Hill CARE Fund for IND-enabling work.SEC 8-K
2026-05-25partnershipAPVO455 · Collaboration and supply agreement with Niowave to develop combination product using APVO455 and Actinium-225.SEC 8-K
2026-01-08partnershipEntered $60M standby equity purchase agreement with Yorkville to fund clinical and preclinical milestones.SEC 8-K
Q4conferencedata presentationsecondaryPhase 1/2mipletamig · Presentation of RAINIER trial Cohort 3 findings at a major medical conference.SEC 8-K
3Q2024trial initiationsecondaryPhase 1/2mipletamig · RAINIER Phase 1b/2 trial initiatedSEC 8-K

Approved drugs (0)

none — clinical-stage

Capital structure — dilution & financing

Shares out: 1,246,105 · 3 offerings/1y · 2 PIPEs

2026-06-308-Kmaterial_agreement
2026-05-278-Kprivate_placement
2026-01-30EFFECTshelf_effective
2026-01-30424B4offering
2026-01-28S-1shelf_registration
2026-01-098-Kprivate_placement
2025-11-25424B4offering

🔒 Positioning — Pro

Short interest / days-to-cover, insider buys & sells.

Upgrade to Pro

🔒 Top holders — Pro

Institutional ownership + quarter-over-quarter accumulation/trimming.

Upgrade to Pro

Wall St ratings

strong buy · target $26 (+473% upside) · 2 analysts

no recent rating changes

Competitors — CD123

none identified

Recent news

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.